Publications by authors named "S Pillozzi"
Background: Platinum chemotherapy (CT) remains the backbone of systemic therapy for patients with small-cell lung cancer (SCLC). The nucleotide excision repair (NER) pathway plays a central role in the repair of the DNA damage exerted by platinum agents. Alteration in this repair mechanism may affect patients' survival.
View Article and Find Full Text PDFArticle Synopsis
- Hyponatremia is known to indicate survival chances in metastatic non-small cell lung cancer (mNSCLC), but the effects of normal sodium levels had not been previously studied until this research.
- The study involved 88 mNSCLC patients treated with immune checkpoint inhibitors (ICIs) and analyzed how sodium levels affected their treatment responses and overall survival.
- Results showed that patients with sodium levels ≥140 mEq/L had significantly better progression-free survival (7.0 months vs. 2.1 months) and overall survival (15.6 months vs. 6.8 months), suggesting low sodium levels are linked to worse outcomes in mNSCLC.
Colorectal cancer (CRC) represents a global health threat, standing as the second leading cause of cancer-related death worldwide. Targeted therapies brought new hope for the metastatic stage, which historically bore a very poor prognosis. Human epidermal growth receptor 2 (HER2) overexpression concerns about 5 % of the metastatic CRC (mCRC) patients, including both gene amplifications and point mutations.
View Article and Find Full Text PDFBackground/aim: Cutaneous squamous cell carcinoma (SCC) is a common skin cancer with significant morbidity and mortality, particularly in advanced stages. Treatment options for metastatic cutaneous SCC in very elderly patients are limited due to concerns about treatment tolerability and potential adverse effects.
Case Report: We report the case of a 90-year-old female patient with metastatic cutaneous SCC who was treated with cemiplimab, a monoclonal antibody (m-Ab) against programmed cell death protein 1 (PD-1), in combination with radiotherapy.
Globally, more than 1 million new cases of gastric cancer were estimated in 2020, ranking fourth in cancer mortality. Currently although in resectable gastric cancer and esophagogastric junction (EGJ) adenocarcinoma a perioperative triplet chemotherapy regimen including a fluoropyrimidine, a platinum compound and docetaxel (FLOT) demonstrated a better overall survival, the survival rate is still very low, and a massive effort is still required to improve clinical prognosis. High microsatellite instability (MSI-H) status in gastric cancer is a favorable prognostic factor but poor data are available on its predictive role for perioperative FLOT chemotherapy in resectable gastric cancer.
View Article and Find Full Text PDF